Targets And Emerging Therapies For Schizophrenia Jeffrey S Albert by Jeffrey S. Albert, Michael W. Wood 9780470322826, 9781118309421, 0470322829, 1118309421 instant download after payment.

New and emerging directions in pharmaceutical research to better treat schizophrenia

Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical research for drug targeting and discovery in order to find more effective treatments for schizophrenia, one of the most serious and widespread psychiatric diseases.

Targets and Emerging Therapies for Schizophrenia presents the basics of schizophrenia, drug targets for the disease, and potential new drugs and therapeutics. It begins with a discussion of prevalence and etiology. Then, it describes therapies such as dopamine agonists and phosphodiesterase (PDE) inhibitors as well as growing research aimed at addressing untreated symptoms. Next, the authors discuss receptor modulators, inhibitors, and targeting strategies for drug discovery. Both the neurobiological and chemical aspects of all major pharmacological targets are examined.

With contributions from an international team of pioneering pharmaceutical researchers, this book compiles the current knowledge in the field, setting the stage for new breakthroughs in the treatment of schizophrenia. Targets and Emerging Therapies for Schizophrenia:

• Provides a comprehensive resource for neuro-drug discovery and the development of molecular targets for schizophrenia treatment
• Draws from chemistry, biology, and pharmacology for more effective drug targeting and discovery
• Explores a wide range of receptors and molecular targets, including dopamine, PDEs, and neuropeptides

With Targets and Emerging Therapies for Schizophrenia as their guide, drug discovery and development scientists have the information they need to advance their own research so that new, more effective treatments for schizophrenia will soon be a reality.Content:
Chapter 1 Dopaminergic Hypothesis of Schizophrenia: A Historical Perspective (pages 5–35): Aurelija Jucaite and Svante Nyberg
Chapter 2 Dopamine D2/D3 Partial Agonists as Antipsychotics (pages 37–49): Philip G. Strange
Chapter 3 D1/D5 Dopamine Agonists as Pharmacotherapy for Schizophrenia (pages 51–84): Kevin N. Boyd and Richard B. Mailman
Chapter 4 Phosphodiesterase Inhibitors as a Novel Therapeutic Approach for Schizophrenia (pages 85–113): Judith A. Siuciak and William J. Pitts
Chapter 5 Glutamatergic Synaptic Dysregulation in Schizophrenia (pages 115–142): Joseph T. Coyle, Alo Basu and Michael Benneyworth
Chapter 6 Metabotropic Glutamate 2/3 Receptor Agonists and Positive Allosteric Modulators of Metabotropic Glutamate Receptor 2 as Novel Agents for the Treatment of Schizophrenia (pages 143–185): Gerard J. Marek, Bruce J. Kinon, David L. McKinzie, Jeffrey M. Schkeryantz and James A. Monn
Chapter 7 AMPA Receptor Positive Modulators (pages 187–231): John A. Morrow, John K. F. Maclean and Craig Jamieson
Chapter 8 Progress in the Exploration and Development of GlyT1 Inhibitors for Schizophrenia (pages 233–254): Jeffrey S. Albert and Michael W. Wood
Chapter 9 Combined Dopamine D2 and 5?Hydroxytryptamine (5?HT)1A Receptor Strategies for the Treatment of Schizophrenia: A Pharmacological and Chemical Perspective (pages 255–272): Andrew C. McCreary, Roelof W. Feenstra and Caitlin A. Jones
Chapter 10 5?HT2C and 5?HT6 Receptor Targeted Emerging Approaches in Schizophrenia (pages 273–294): Sharon Rosenzweig?Lipson, John Dunlop, Lee E. Schechter, Thomas A. Comery, Jonathan Gross and Karen L. Marquis
Chapter 11 The Cholinergic Hypothesis: An Introduction to the Hypothesis and a Short History (pages 295–318): Joseph I. Friedman, Isabella Kanellopoulou and Vladan Novakovic
Chapter 12 ?7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia (pages 319–354): Mihaly Hajos and Bruce N. Rogers
Chapter 13 Muscarinic Acetylcholine Receptors as Novel Targets for the Development of Therapeutics for Schizophrenia (pages 355–379): Christian C. Felder, David L. McKinzie, Richard C. Thompson and Bin Liu
Chapter 14 Will Modulation of Neuropeptide Receptors Produce the Next Generation of Antipsychotic Drugs? A Focus on the Neurokinin and Neurotensin Systems (pages 381–424): Lee A. Dawson, Paul W. Smith and Jeannette M. Watson
Chapter 15 GABA and Schizophrenia (pages 425–467): John H. Kehne and George D. Maynard